<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/">
<channel>
<title>心血管高分期刊</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_medium=rss&amp;ff=20240821101042&amp;v=2.18.0.post9+e462414&amp;utm_source=Chrome&amp;utm_campaign=pubmed-2&amp;fc=20230708114047&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-
    <description>心血管高分期刊: Latest results from PubMed</description>
<atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_medium=rss&amp;ff=20240821101042&amp;v=2.18.0.post9+e462414&amp;utm_source=Chrome&amp;utm_campaign=pubmed-2&amp;fc=20230708114047&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-" rel="self"></atom:link>
<docs>http://www.rssboard.org/rss-specification</docs>
<generator>PubMed RSS feeds (2.18.0.post9+e462414)</generator>
<language>en</language>
<lastbuilddate>Wed, 21 Aug 2024 14:10:43 +0000</lastbuilddate>
<pubDate>Tue, 20 Aug 2024 06:00:00 -0400</pubDate>
<ttl>120</ttl>
<item>
<title>Hot topics in thromboembolic risk prevention, heart failure monitoring, and cardiomyopathy risk stratification</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39164016/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240821101042&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Aug 21;45(32):2899-2903. doi: 10.1093/eurheartj/ehae522.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39164016/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240821101042&v=2.18.0.post9+e462414">39164016</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae522>10.1093/eurheartj/ehae522</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39164016</guid>
<pubDate>Tue, 20 Aug 2024 06:00:00 -0400</pubDate>
<dc:creator>Filippo Crea</dc:creator>
<dc:date>2024-08-20</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Hot topics in thromboembolic risk prevention, heart failure monitoring, and cardiomyopathy risk stratification</dc:title>
<dc:identifier>pmid:39164016</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae522</dc:identifier>
</item>
<item>
<title>Vaginal Lactobacillus fatty acid response mechanisms reveal a metabolite-targeted strategy for bacterial vaginosis treatment</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39163861/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240821101042&amp;v=2.18.0.post9+e462414
      <description>Bacterial vaginosis (BV), a common syndrome characterized by Lactobacillus-deficient vaginal microbiota, is associated with adverse health outcomes. BV often recurs after standard antibiotic therapy in part because antibiotics promote microbiota dominance by Lactobacillus iners instead of Lactobacillus crispatus, which has more beneficial health associations. Strategies to promote L. crispatus and inhibit L. iners are thus needed. We show that oleic acid (OA) and similar long-chain fatty acids...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Aug 14:S0092-8674(24)00823-7. doi: 10.1016/j.cell.2024.07.029. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Bacterial vaginosis (BV), a common syndrome characterized by Lactobacillus-deficient vaginal microbiota, is associated with adverse health outcomes. BV often recurs after standard antibiotic therapy in part because antibiotics promote microbiota dominance by Lactobacillus iners instead of Lactobacillus crispatus, which has more beneficial health associations. Strategies to promote L. crispatus and inhibit L. iners are thus needed. We show that oleic acid (OA) and similar long-chain fatty acids simultaneously inhibit L. iners and enhance L. crispatus growth. These phenotypes require OA-inducible genes conserved in L. crispatus and related lactobacilli, including an oleate hydratase (ohyA) and putative fatty acid efflux pump (farE). FarE mediates OA resistance, while OhyA is robustly active in the vaginal microbiota and enhances bacterial fitness by biochemically sequestering OA in a derivative form only ohyA-harboring organisms can exploit. OA promotes L. crispatus dominance more effectively than antibiotics in an in vitro BV model, suggesting a metabolite-based treatment approach.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39163861/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240821101042&v=2.18.0.post9+e462414">39163861</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.07.029>10.1016/j.cell.2024.07.029</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39163861</guid>
<pubDate>Tue, 20 Aug 2024 06:00:00 -0400</pubDate>
<dc:creator>Meilin Zhu</dc:creator>
<dc:creator>Matthew W Frank</dc:creator>
<dc:creator>Christopher D Radka</dc:creator>
<dc:creator>Sarah Jeanfavre</dc:creator>
<dc:creator>Jiawu Xu</dc:creator>
<dc:creator>Megan W Tse</dc:creator>
<dc:creator>Julian Avila Pacheco</dc:creator>
<dc:creator>Jae Sun Kim</dc:creator>
<dc:creator>Kerry Pierce</dc:creator>
<dc:creator>Amy Deik</dc:creator>
<dc:creator>Fatima Aysha Hussain</dc:creator>
<dc:creator>Joseph Elsherbini</dc:creator>
<dc:creator>Salina Hussain</dc:creator>
<dc:creator>Nondumiso Xulu</dc:creator>
<dc:creator>Nasreen Khan</dc:creator>
<dc:creator>Vanessa Pillay</dc:creator>
<dc:creator>Caroline M Mitchell</dc:creator>
<dc:creator>Krista L Dong</dc:creator>
<dc:creator>Thumbi Ndung'u</dc:creator>
<dc:creator>Clary B Clish</dc:creator>
<dc:creator>Charles O Rock</dc:creator>
<dc:creator>Paul C Blainey</dc:creator>
<dc:creator>Seth M Bloom</dc:creator>
<dc:creator>Douglas S Kwon</dc:creator>
<dc:date>2024-08-20</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Vaginal Lactobacillus fatty acid response mechanisms reveal a metabolite-targeted strategy for bacterial vaginosis treatment</dc:title>
<dc:identifier>pmid:39163861</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.07.029</dc:identifier>
</item>
<item>
<title>Mining human microbiomes reveals an untapped source of peptide antibiotics</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39163860/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240821101042&amp;v=2.18.0.post9+e462414
      <description>Drug-resistant bacteria are outpacing traditional antibiotic discovery efforts. Here, we computationally screened 444,054 previously reported putative small protein families from 1,773 human metagenomes for antimicrobial properties, identifying 323 candidates encoded in small open reading frames (smORFs). To test our computational predictions, 78 peptides were synthesized and screened for antimicrobial activity in vitro, with 70.5% displaying antimicrobial activity. As these compounds were...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Aug 16:S0092-8674(24)00802-X. doi: 10.1016/j.cell.2024.07.027. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Drug-resistant bacteria are outpacing traditional antibiotic discovery efforts. Here, we computationally screened 444,054 previously reported putative small protein families from 1,773 human metagenomes for antimicrobial properties, identifying 323 candidates encoded in small open reading frames (smORFs). To test our computational predictions, 78 peptides were synthesized and screened for antimicrobial activity in vitro, with 70.5% displaying antimicrobial activity. As these compounds were different compared with previously reported antimicrobial peptides, we termed them smORF-encoded peptides (SEPs). SEPs killed bacteria by targeting their membrane, synergizing with each other, and modulating gut commensals, indicating a potential role in reconfiguring microbiome communities in addition to counteracting pathogens. The lead candidates were anti-infective in both murine skin abscess and deep thigh infection models. Notably, prevotellin-2 from Prevotella copri presented activity comparable to the commonly used antibiotic polymyxin B. Our report supports the existence of hundreds of antimicrobials in the human microbiome amenable to clinical translation.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39163860/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240821101042&v=2.18.0.post9+e462414">39163860</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.07.027>10.1016/j.cell.2024.07.027</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39163860</guid>
<pubDate>Tue, 20 Aug 2024 06:00:00 -0400</pubDate>
<dc:creator>Marcelo D T Torres</dc:creator>
<dc:creator>Erin F Brooks</dc:creator>
<dc:creator>Angela Cesaro</dc:creator>
<dc:creator>Hila Sberro</dc:creator>
<dc:creator>Matthew O Gill</dc:creator>
<dc:creator>Cosmos Nicolaou</dc:creator>
<dc:creator>Ami S Bhatt</dc:creator>
<dc:creator>Cesar de la Fuente-Nunez</dc:creator>
<dc:date>2024-08-20</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Mining human microbiomes reveals an untapped source of peptide antibiotics</dc:title>
<dc:identifier>pmid:39163860</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.07.027</dc:identifier>
</item>
<item>
<title>Correction to: An autoantibody profile detects Brugada syndrome and identifies abnormally expressed myocardial proteins</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39163133/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240821101042&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Aug 20:ehae395. doi: 10.1093/eurheartj/ehae395. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39163133/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240821101042&v=2.18.0.post9+e462414">39163133</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae395>10.1093/eurheartj/ehae395</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39163133</guid>
<pubDate>Tue, 20 Aug 2024 06:00:00 -0400</pubDate>
<dc:date>2024-08-20</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Correction to: An autoantibody profile detects Brugada syndrome and identifies abnormally expressed myocardial proteins</dc:title>
<dc:identifier>pmid:39163133</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae395</dc:identifier>
</item>
<item>
<title>Correction to: Intravenous iron for heart failure, iron deficiency definitions, and clinical response: the IRONMAN trial</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39163128/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240821101042&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Aug 20:ehae243. doi: 10.1093/eurheartj/ehae243. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39163128/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240821101042&v=2.18.0.post9+e462414">39163128</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae243>10.1093/eurheartj/ehae243</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39163128</guid>
<pubDate>Tue, 20 Aug 2024 06:00:00 -0400</pubDate>
<dc:date>2024-08-20</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Correction to: Intravenous iron for heart failure, iron deficiency definitions, and clinical response: the IRONMAN trial</dc:title>
<dc:identifier>pmid:39163128</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae243</dc:identifier>
</item>
<item>
<title>The ESC Working Group on Cellular Biology of the Heart</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39162572/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240821101042&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Aug 20:ehae017. doi: 10.1093/eurheartj/ehae017. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39162572/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240821101042&v=2.18.0.post9+e462414">39162572</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae017>10.1093/eurheartj/ehae017</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39162572</guid>
<pubDate>Tue, 20 Aug 2024 06:00:00 -0400</pubDate>
<dc:creator>Cinzia Perrino</dc:creator>
<dc:creator>Maurizio Pesce</dc:creator>
<dc:creator>Sean M Davidson</dc:creator>
<dc:date>2024-08-20</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>The ESC Working Group on Cellular Biology of the Heart</dc:title>
<dc:identifier>pmid:39162572</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae017</dc:identifier>
</item>
<item>
<title>Triglycerides: the past, the present, and the future</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39162355/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240821101042&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Aug 20:ehae515. doi: 10.1093/eurheartj/ehae515. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39162355/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240821101042&v=2.18.0.post9+e462414">39162355</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae515>10.1093/eurheartj/ehae515</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39162355</guid>
<pubDate>Tue, 20 Aug 2024 06:00:00 -0400</pubDate>
<dc:creator>Eugene Braunwald</dc:creator>
<dc:date>2024-08-20</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Triglycerides: the past, the present, and the future</dc:title>
<dc:identifier>pmid:39162355</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae515</dc:identifier>
</item>
<item>
<title>Randomized Crossover Trial of 2-Week Ketone Ester Treatment in Patients With Type 2 Diabetes and Heart Failure With Preserved Ejection Fraction</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39162035/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240821101042&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: In patients with T2DM and HFpEF, a 2-week oral KE treatment increased cardiac output and reduced cardiac filling pressures and ventricular stiffness. At peak exercise, KE treatment markedly decreased pulmonary capillary wedge pressure and improved pressure-flow relationship. Modulation of circulating ketone levels is a potential new treatment modality for patients with T2DM and HFpEF.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Aug 20. doi: 10.1161/CIRCULATIONAHA.124.069732. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Heart failure with preserved ejection fraction (HFpEF) is a major cause of morbidity and mortality in patients with type 2 diabetes (T2DM). Acute increases in circulating levels of ketone body 3-hydroxybutyrate have beneficial acute hemodynamic effects in patients without T2DM with chronic heart failure with reduced ejection fraction. However, the cardiovascular effects of prolonged oral ketone ester (KE) treatment in patients with T2DM and HFpEF remain unknown.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: A total of 24 patients with T2DM and HFpEF completed a 6-week randomized, double-blind crossover study. All patients received 2 weeks of KE treatment (25 g D-ß-hydroxybutyrate-(R)-1,3-butanediol × 4 daily) and isocaloric and isovolumic placebo, separated by a 2-week washout period. At the end of each treatment period, patients underwent right heart catheterization, echocardiography, and blood samples at trough levels of intervention, and then during a 4-hour resting period after a single dose. A subsequent second dose was administered, followed by an exercise test. The primary end point was cardiac output during the 4-hour rest period.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: During the 4-hour resting period, circulating 3-hydroxybutyrate levels were 10-fold higher after KE treatment (1010±56 µmol/L; <i>P</i>&lt;0.001) compared with placebo (91±55 µmol/L). Compared with placebo, KE treatment increased cardiac output by 0.2 L/min (95% CI, 0.1 to 0.3) during the 4-hour period and decreased pulmonary capillary wedge pressure at rest by 1 mm Hg (95% CI, -2 to 0) and at peak exercise by 5 mm Hg (95% CI, -9 to -1). KE treatment decreased the pressure-flow relationship (∆ pulmonary capillary wedge pressure/∆ cardiac output) significantly during exercise (<i>P</i>&lt;0.001) and increased stroke volume by 10 mL (95% CI, 0 to 20) at peak exercise. KE right-shifted the left ventricular end-diastolic pressure-volume relationship, suggestive of reduced left ventricular stiffness and improved compliance. Favorable hemodynamic responses of KE treatment were also observed in patients treated with sodium-glucose transporter-2 inhibitors and glucagon-like peptide-1 analogs.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: In patients with T2DM and HFpEF, a 2-week oral KE treatment increased cardiac output and reduced cardiac filling pressures and ventricular stiffness. At peak exercise, KE treatment markedly decreased pulmonary capillary wedge pressure and improved pressure-flow relationship. Modulation of circulating ketone levels is a potential new treatment modality for patients with T2DM and HFpEF.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">REGISTRATION: URL: https://www.clinicaltrials.gov; Unique Identifier: NCT05236335.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39162035/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240821101042&v=2.18.0.post9+e462414">39162035</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.069732>10.1161/CIRCULATIONAHA.124.069732</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39162035</guid>
<pubDate>Tue, 20 Aug 2024 06:00:00 -0400</pubDate>
<dc:creator>Nigopan Gopalasingam</dc:creator>
<dc:creator>Kristoffer Berg-Hansen</dc:creator>
<dc:creator>Kristian Hylleberg Christensen</dc:creator>
<dc:creator>Bertil T Ladefoged</dc:creator>
<dc:creator>Steen Hvitfeldt Poulsen</dc:creator>
<dc:creator>Mads Jønsson Andersen</dc:creator>
<dc:creator>Barry Borlaug</dc:creator>
<dc:creator>Roni Nielsen</dc:creator>
<dc:creator>Niels Møller</dc:creator>
<dc:creator>Henrik Wiggers</dc:creator>
<dc:date>2024-08-20</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Randomized Crossover Trial of 2-Week Ketone Ester Treatment in Patients With Type 2 Diabetes and Heart Failure With Preserved Ejection Fraction</dc:title>
<dc:identifier>pmid:39162035</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.069732</dc:identifier>
</item>
<item>
<title>Correction to: Diagnosis and Management of Cardiac Sarcoidosis: A Scientific Statement From the American Heart Association</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39159229/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240821101042&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Aug 20;150(8):e197. doi: 10.1161/CIR.0000000000001275. Epub 2024 Aug 19.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39159229/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240821101042&v=2.18.0.post9+e462414">39159229</a> | DOI:<a href=https://doi.org/10.1161/CIR.0000000000001275>10.1161/CIR.0000000000001275</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39159229</guid>
<pubDate>Mon, 19 Aug 2024 06:00:00 -0400</pubDate>
<dc:date>2024-08-19</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Correction to: Diagnosis and Management of Cardiac Sarcoidosis: A Scientific Statement From the American Heart Association</dc:title>
<dc:identifier>pmid:39159229</dc:identifier>
<dc:identifier>doi:10.1161/CIR.0000000000001275</dc:identifier>
</item>
<item>
<title>Correction to: Past, Present, and Future of CTA</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39159228/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240821101042&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Aug 20;150(8):e199. doi: 10.1161/CIR.0000000000001283. Epub 2024 Aug 19.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39159228/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240821101042&v=2.18.0.post9+e462414">39159228</a> | DOI:<a href=https://doi.org/10.1161/CIR.0000000000001283>10.1161/CIR.0000000000001283</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39159228</guid>
<pubDate>Mon, 19 Aug 2024 06:00:00 -0400</pubDate>
<dc:date>2024-08-19</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Correction to: Past, Present, and Future of CTA</dc:title>
<dc:identifier>pmid:39159228</dc:identifier>
<dc:identifier>doi:10.1161/CIR.0000000000001283</dc:identifier>
</item>
<item>
<title>Correction to: 2024 AHA/ACC/AMSSM/HRS/PACES/SCMR Guideline for the Management of Hypertrophic Cardiomyopathy: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39159227/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240821101042&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Aug 20;150(8):e198. doi: 10.1161/CIR.0000000000001277. Epub 2024 Aug 19.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39159227/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240821101042&v=2.18.0.post9+e462414">39159227</a> | DOI:<a href=https://doi.org/10.1161/CIR.0000000000001277>10.1161/CIR.0000000000001277</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39159227</guid>
<pubDate>Mon, 19 Aug 2024 06:00:00 -0400</pubDate>
<dc:date>2024-08-19</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Correction to: 2024 AHA/ACC/AMSSM/HRS/PACES/SCMR Guideline for the Management of Hypertrophic Cardiomyopathy: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines</dc:title>
<dc:identifier>pmid:39159227</dc:identifier>
<dc:identifier>doi:10.1161/CIR.0000000000001277</dc:identifier>
</item>
<item>
<title>Does PPG, the Other Dimension to FFR, Better Predict Post-PCI Results?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39159226/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240821101042&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Aug 20;150(8):598-599. doi: 10.1161/CIRCULATIONAHA.124.070439. Epub 2024 Aug 19.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39159226/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240821101042&v=2.18.0.post9+e462414">39159226</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.070439>10.1161/CIRCULATIONAHA.124.070439</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39159226</guid>
<pubDate>Mon, 19 Aug 2024 06:00:00 -0400</pubDate>
<dc:creator>Morton J Kern</dc:creator>
<dc:creator>Arnold H Seto</dc:creator>
<dc:date>2024-08-19</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Does PPG, the Other Dimension to FFR, Better Predict Post-PCI Results?</dc:title>
<dc:identifier>pmid:39159226</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.070439</dc:identifier>
</item>
<item>
<title>Congenital Heart Surgery: In Rapid Evolution</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39159225/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240821101042&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Aug 20;150(8):583-585. doi: 10.1161/CIRCULATIONAHA.124.068655. Epub 2024 Aug 19.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39159225/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240821101042&v=2.18.0.post9+e462414">39159225</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.068655>10.1161/CIRCULATIONAHA.124.068655</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39159225</guid>
<pubDate>Mon, 19 Aug 2024 06:00:00 -0400</pubDate>
<dc:creator>Pedro J Del Nido</dc:creator>
<dc:date>2024-08-19</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Congenital Heart Surgery: In Rapid Evolution</dc:title>
<dc:identifier>pmid:39159225</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.068655</dc:identifier>
</item>
<item>
<title>Diagnosis of Brugada Syndrome With a Sodium-Channel-Blocker Test: Who Should Be Tested? Who Should Not?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39159224/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240821101042&amp;v=2.18.0.post9+e462414
      <description>Intravenous infusion of sodium-channel blockers (SCB) with either ajmaline, flecainide, procainamide, or pilsicainide to unmask the ECG of Brugada syndrome is the drug challenge most commonly used for diagnostic purposes when investigating cases possibly related to inherited arrhythmia syndromes. For a patient undergoing an SCB challenge, the impact of a positive result goes well beyond its diagnostic implications. It is, therefore, appropriate to question who should undergo a SCB test to...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Aug 20;150(8):642-650. doi: 10.1161/CIRCULATIONAHA.124.069138. Epub 2024 Aug 19.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Intravenous infusion of sodium-channel blockers (SCB) with either ajmaline, flecainide, procainamide, or pilsicainide to unmask the ECG of Brugada syndrome is the drug challenge most commonly used for diagnostic purposes when investigating cases possibly related to inherited arrhythmia syndromes. For a patient undergoing an SCB challenge, the impact of a positive result goes well beyond its diagnostic implications. It is, therefore, appropriate to question who should undergo a SCB test to diagnose or exclude Brugada syndrome and, perhaps more importantly, who should not. We present a critical review of the benefits and drawbacks of the SCB challenge when performed in cardiac arrest survivors, patients presenting with syncope, family members of probands with confirmed Brugada syndrome, and asymptomatic patients with suspicious ECG.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39159224/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240821101042&v=2.18.0.post9+e462414">39159224</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.069138>10.1161/CIRCULATIONAHA.124.069138</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39159224</guid>
<pubDate>Mon, 19 Aug 2024 06:00:00 -0400</pubDate>
<dc:creator>Sami Viskin</dc:creator>
<dc:creator>Ehud Chorin</dc:creator>
<dc:creator>Raphael Rosso</dc:creator>
<dc:creator>Ahmad S Amin</dc:creator>
<dc:creator>Arthur A Wilde</dc:creator>
<dc:date>2024-08-19</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Diagnosis of Brugada Syndrome With a Sodium-Channel-Blocker Test: Who Should Be Tested? Who Should Not?</dc:title>
<dc:identifier>pmid:39159224</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.069138</dc:identifier>
</item>
<item>
<title>Highlights From the &lt;em>;Circulation&lt;/em>; Family of Journals</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39159223/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240821101042&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Aug 20;150(8):651-656. doi: 10.1161/CIRCULATIONAHA.124.071487. Epub 2024 Aug 19.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39159223/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240821101042&v=2.18.0.post9+e462414">39159223</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.071487>10.1161/CIRCULATIONAHA.124.071487</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39159223</guid>
<pubDate>Mon, 19 Aug 2024 06:00:00 -0400</pubDate>
<dc:date>2024-08-19</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Highlights From the &lt;em>;Circulation&lt;/em>; Family of Journals</dc:title>
<dc:identifier>pmid:39159223</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.071487</dc:identifier>
</item>
<item>
<title>Letter by Zhang et al Regarding Article, "Patient-Level Pooled Analysis of Endovascular Ultrasound Renal Denervation or a Sham Procedure 6 Months After Medication Escalation: The RADIANCE Clinical Trial Program"</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39159222/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240821101042&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Aug 20;150(8):e181-e182. doi: 10.1161/CIRCULATIONAHA.124.069623. Epub 2024 Aug 19.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39159222/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240821101042&v=2.18.0.post9+e462414">39159222</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.069623>10.1161/CIRCULATIONAHA.124.069623</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39159222</guid>
<pubDate>Mon, 19 Aug 2024 06:00:00 -0400</pubDate>
<dc:creator>Zhipeng Zhang</dc:creator>
<dc:creator>Kai Liu</dc:creator>
<dc:creator>Xiaoping Chen</dc:creator>
<dc:date>2024-08-19</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Letter by Zhang et al Regarding Article, "Patient-Level Pooled Analysis of Endovascular Ultrasound Renal Denervation or a Sham Procedure 6 Months After Medication Escalation: The RADIANCE Clinical Trial Program"</dc:title>
<dc:identifier>pmid:39159222</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.069623</dc:identifier>
</item>
<item>
<title>Junctophilin-2 Regulates Mitochondrial Metabolism</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39159221/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240821101042&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Aug 20;150(8):657-660. doi: 10.1161/CIRCULATIONAHA.123.064343. Epub 2024 Aug 19.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39159221/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240821101042&v=2.18.0.post9+e462414">39159221</a> | PMC:<a href="https://www.ncbi.nlm.nih.gov/pmc/PMC11335313/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240821101042&v=2.18.0.post9+e462414">PMC11335313</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.064343>10.1161/CIRCULATIONAHA.123.064343</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39159221</guid>
<pubDate>Mon, 19 Aug 2024 06:00:00 -0400</pubDate>
<dc:creator>Sasha Z Prisco</dc:creator>
<dc:creator>Lynn M Hartweck</dc:creator>
<dc:creator>Felipe Kazmirczak</dc:creator>
<dc:creator>Jenna B Mendelson</dc:creator>
<dc:creator>Stephanie L Deng</dc:creator>
<dc:creator>Madelyn Blake</dc:creator>
<dc:creator>Satadru K Lahiri</dc:creator>
<dc:creator>Xander H T Wehrens</dc:creator>
<dc:creator>Kurt W Prins</dc:creator>
<dc:date>2024-08-19</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Junctophilin-2 Regulates Mitochondrial Metabolism</dc:title>
<dc:identifier>pmid:39159221</dc:identifier>
<dc:identifier>pmc:PMC11335313</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.064343</dc:identifier>
</item>
<item>
<title>More questions than answers after NOTION-2</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39158500/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240821101042&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Aug 19:ehae527. doi: 10.1093/eurheartj/ehae527. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39158500/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240821101042&v=2.18.0.post9+e462414">39158500</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae527>10.1093/eurheartj/ehae527</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39158500</guid>
<pubDate>Mon, 19 Aug 2024 06:00:00 -0400</pubDate>
<dc:creator>Victor Dayan</dc:creator>
<dc:creator>Sanjay Kaul</dc:creator>
<dc:date>2024-08-19</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>More questions than answers after NOTION-2</dc:title>
<dc:identifier>pmid:39158500</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae527</dc:identifier>
</item>
<item>
<title>Underpowered trials: redundant or useful as a canary in the coal mine?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39158494/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240821101042&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Aug 19:ehae528. doi: 10.1093/eurheartj/ehae528. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39158494/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240821101042&v=2.18.0.post9+e462414">39158494</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae528>10.1093/eurheartj/ehae528</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39158494</guid>
<pubDate>Mon, 19 Aug 2024 06:00:00 -0400</pubDate>
<dc:creator>Troels Højsgaard Jørgensen</dc:creator>
<dc:creator>Hans Gustav Hørsted Thyregod</dc:creator>
<dc:creator>Ole De Backer</dc:creator>
<dc:date>2024-08-19</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Underpowered trials: redundant or useful as a canary in the coal mine?</dc:title>
<dc:identifier>pmid:39158494</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae528</dc:identifier>
</item>
<item>
<title>Loop diuretics in cardiovascular disease: friend or foe?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39158480/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240821101042&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Aug 19:ehae483. doi: 10.1093/eurheartj/ehae483. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39158480/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240821101042&v=2.18.0.post9+e462414">39158480</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae483>10.1093/eurheartj/ehae483</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39158480</guid>
<pubDate>Mon, 19 Aug 2024 06:00:00 -0400</pubDate>
<dc:creator>Annika Rosengren</dc:creator>
<dc:date>2024-08-19</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Loop diuretics in cardiovascular disease: friend or foe?</dc:title>
<dc:identifier>pmid:39158480</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae483</dc:identifier>
</item>
<item>
<title>Multi-stakeholder workshop on reducing population-wide dietary sodium intake in Nigeria</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39158473/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240821101042&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Aug 19:ehae461. doi: 10.1093/eurheartj/ehae461. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39158473/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240821101042&v=2.18.0.post9+e462414">39158473</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae461>10.1093/eurheartj/ehae461</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39158473</guid>
<pubDate>Mon, 19 Aug 2024 06:00:00 -0400</pubDate>
<dc:creator>Chisom Obiezu-Umeh</dc:creator>
<dc:creator>Mark D Huffman</dc:creator>
<dc:creator>Dike Ojji</dc:creator>
<dc:date>2024-08-19</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Multi-stakeholder workshop on reducing population-wide dietary sodium intake in Nigeria</dc:title>
<dc:identifier>pmid:39158473</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae461</dc:identifier>
</item>





























</channel>
</rss>